PDAC’s unique tumor immune signature is characterized by a prevalence of immune suppressor cells like tumor-associated macrophages (TAMs), T regulatory (Treg) cells, CD4+ TH2 cells, and myeloid-derived suppressor cells (MDSCs), which collectively hinder the activation, proliferation, and effectiveness of effector T cells, ultimately inhibiting anti-tumor T cell immunity and promoting PDAC progression (58). This evidence concerns the gene CD4 and neoplasm.